Submitting Author(s)

Catherine F. Alapatt, Rowan UniversityFollow
Klaudia Matanaj, Rowan UniversityFollow

Updates to Acne Vulgaris Treatment: A Review of a Topical Androgen Receptor Inhibitor

Date of Presentation

5-2-2024 12:00 AM

College

Rowan-Virtua School of Osteopathic Medicine

Poster Abstract

Acne Vulgaris is an inflammatory skin disorder that is common among adolescents and young adults. Acne is defined as a chronic inflammatory dermatosis which consists of open comedones (blackheads), closed comedones (whiteheads) and inflammatory lesions.1 There are many ways to combat acne, one of which is to stop the effects of androgens on androgen receptors. Here we will review Clascoterone, a medication approved for the treatment of acne. Clascoterone is the first topical medication to target the hormonal pathogenesis of acne. It was approved by the FDA in 2020 and is effective in treatment of acne vulgaris in patients 12 years of age and older.2

Keywords

Acne vulgaris, androgen receptor inhibitor, clascoterone, topical androgen receptor inhibitor, Androgen Receptor Antagonists, Cutaneous Administration, Topical Administration

Disciplines

Dermatology | Medicine and Health Sciences | Pathological Conditions, Signs and Symptoms | Pharmaceutical Preparations | Skin and Connective Tissue Diseases | Therapeutics

Document Type

Poster